BMJ  2004;328:668 (20 March), doi:10.1136/bmj.38028.520995.63 (published 2 March 2004)

Paper

lactam monotherapy versus lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

¹ Department of Medicine E and Infectious Diseases Unit, Rabin Medical Centre, Beilinson Campus, Petah-Tikva 49100, Israel, ² Department of Medicine E, Rabin Medical Centre, Beilinson Campus, Petah-Tikva

Abstract

Objective To compare lactam monotherapy with lactam-aminoglycoside combination therapy for severe infections.

Data sources Medline, Embase, Lilacs, Cochrane Library, and conference proceedings, to 2003; references of included studies; contact with all authors. No restrictions, such as language, year of publication, or publication status.

Study selection All randomised trials of lactam monotherapy compared with lactam-aminoglycoside combination therapy for patients without neutropenia who fulfilled criteria for sepsis.

Data selection Two reviewers independently applied selection criteria, performed quality assessment, and extracted the data. The primary outcome assessed was all cause fatality by intention to treat. Relative risks were pooled with the random effect model (relative risk < 1 favours monotherapy).

Results 64 trials with 7586 patients were included. There was no difference in all cause fatality (relative risk 0.90, 95% confidence interval 0.77 to 1.06). 12 studies compared the same lactam (1.02, 0.76 to 1.38), and 31 studies compared different lactams (0.85, 0.69 to 1.05). Clinical failure was more common with combination treatment overall (0.87, 0.78 to 0.97) and among studies comparing different lactams (0.76, 0.68 to 0.86). There was no advantage to combination therapy among patients with Gram negative infections (1835 patients) or Pseudomonas aeruginosa infections (426 patients). There was no difference in the rate of development of resistance. Nephrotoxicity was significantly more common with combination therapy (0.36, 0.28 to 0.47). Heterogeneity was not significant for these comparisons.

Conclusions In the treatment of sepsis the addition of an aminoglycoside to lactams should be discouraged. Fatality remains unchanged, while the risk for adverse events is increased.

Introduction

Treatment with a combination of lactam and an aminoglycoside is purported to be superior to lactam alone for sepsis on the basis of potential advantages such as in vitro synergism and prevention of development of resistance.^1-7 Textbooks and guidelines advise the combination for specific pathogens, such as Pseudomonas aeruginosa and other Gram negative bacteria, and for infections commonly caused by these pathogens.^{8 9} In aiming for optimal antibiotic treatment of severe infections, hospital clinicians tend to use combination therapy despite the lack of direct evidence for its effectiveness. Observational studies show that 56% of patients with septic shock in the intensive care unit¹⁰ are given lactam-aminoglycoside combination therapy.

We performed a systematic review and meta-analysis of randomised trials comparing lactam-aminoglycoside combination therapy with lactam monotherapy for severe infections in patients without neutropenia.

Methods

We searched Medline, Embase, Lilacs, the Cochrane Library (all up to March 2003), conference proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (1995-2002), and citations of included trials (see bmj.com for details).

We included all randomised and quasi-randomised trials that compared any lactam monotherapy with any combination of a lactam and an aminoglycoside for severe infections. Severe infection was defined as clinical evidence of infection, plus evidence of a systemic response to infection.¹¹ We excluded studies with a dropout rate above 30%, unless intention to treat analysis was given for mortality or failure outcomes, and studies with more than 15% of patients with neutropenia, neonates, and preterm babies.

The primary outcome assessed was all cause fatality by the end of study follow up and up to 30 days. Secondary outcomes included treatment failure, defined as death, non-resolving primary infection, any modification to allocated antibiotics, or any therapeutic invasive intervention not defined by protocol; bacteriological failure, defined as persistence of primary pathogen; bacterial and fungal superinfections and colonisation; adverse events; and length of hospital stay. We separated studies that compared the same lactam from studies that compared different lactams. We performed subgroup analyses for P aeruginosa infections, any Gram negative infection, bacteraemia, and specific sources of infection.

Two reviewers independently applied inclusion and exclusion criteria and extracted the data. We extracted outcomes by intention to treat, unless the reasons for exclusions were not presented. In this case, we used the presented results (per protocol analysis) in the main analysis and compared them with results using all randomised patients and assuming failure for dropouts. We expected heterogeneity with respect to outcomes and used the random effects model, comparing it to a fixed effect model.¹² The effect of study quality measures was examined through sensitivity analysis.

We examined a funnel plot of the log of the relative risk against the weight to estimate potential selection bias (such as publication bias) and to assess whether effect estimates were associated with study size.

Results

We evaluated 144 eligible randomised trials and included 64 in the review (see bmj.com). The trials included 7586 patients, nearly all adults, and were performed between the years 1968-2001. The median number of patients per trial was 87 (range 20-580). The major conditions were severe sepsis, pneumonia, or Gram negative infections (41 trials), abdominal infections (11 trials), urinary tract infections (7 trials), and Gram positive infections (5 trials). Allocation to antibiotics was empirical in 56 trials. The same lactam was compared in 20 trials, while all other trials compared one lactam to a different, narrower spectrum lactam combined with an aminoglycoside.

All cause fatality—Forty three trials including 5527 patients reported all cause fatality. There was no significant difference between monotherapy and combination therapy when we combined these studies (fig 1). There was no difference among the 12 studies with 1381 patients that compared the same lactam or among studies that compared different lactams. The heterogeneity for this comparison was low.

View larger version (52K): [in this window] [in a new window]   Fig 1 All cause fatality in comparison of lactam monotherapy v lactam-aminoglycoside combination therapy for treatment of sepsis. Log scale of relative risks (95% confidence intervals), random effect model. Studies ordered by weight

 

Treatment failure—We compared clinical and bacteriological failures in 63 and 43 trials, respectively. For both comparisons, monotherapy was not significantly different from combination therapy among studies that compared the same lactam. Monotherapy was significantly superior to combination therapy among studies that compared different lactams. The overall comparison favoured monotherapy for clinical failure (0.87, 0.78 to 0.97; 6616 patients; number needed to treat 34, 20 to 147) and for bacteriological failure (0.86, 0.72 to 1.02; 3511 patients).

Subgroup analysis—Major effectiveness outcomes were compared within the defined patient subgroups: P aeruginosa infections, any Gram negative infection, bacteraemia, non-urinary tract infections, Gram positive infections, and endocarditis. We did not detect an advantage to combination therapy with any subgroup tested (see bmj.com).

Development of resistance—Combination therapy did not lower bacterial superinfection or colonisation rates, which we would have expected if combination therapy prevented the development of resistance. Relative risks tended to favour monotherapy for bacterial superinfections (0.79, 0.59 to 1.06). Rates of fungal superinfection were similar. Twenty six studies reported coverage rates of the allocated treatment, although outcomes were not related to coverage. Among studies with different lactams, the monotherapy lactam provided broader coverage than the combination lactam in 13 studies, the opposite occurring in two studies. Combined coverage of the lactam and the aminoglycoside equalled monotherapy in these studies.

Dropouts and adverse events—The dropout rate was 12.6% and similar in both study groups (1.01, 0.85 to 1.20, 24 studies, 3631 patients). Few patients (2%) discontinued treatment because of adverse events with no difference between study groups (0.89, 0.52 to 1.52, 15 studies, 3042 patients). Nephrotoxicity was more common with combination therapy in nearly all studies, and the combined relative risk was 0.36 (0.28 to 0.47, fig 2), corresponding to a number needed to harm of 15 (14 to 17) for combination therapy.

View larger version (60K): [in this window] [in a new window]   Fig 2 Adverse events: nephrotoxicity in comparison of lactam monotherapy v lactam-aminoglycoside combination therapy for treatment of sepsis. Log scale of relative risks (95% confidence intervals), random effect model. Studies ordered by weight

 

Sensitivity analysis—Sensitivity analyses were carried out for measures of study quality. All sensitivity comparisons were non-significant. The advantage of monotherapy was more significant in trials that used some type of blinding. The funnel plot for treatment failure generated a nearly symmetrical "funnel distribution" (see bmj.com).

Discussion

Main findings
In this systematic review of all randomised trials we have shown that lactam-aminoglycoside combination therapy and lactam monotherapy for the treatment of sepsis have similar effects in patients without neutropenia.

Twenty trials compared the same lactam. All cause fatality, the most significant and objective outcome, was not reduced by the addition of aminoglycosides. Clinical and bacteriological failure, which may be prone to bias with non-blinded trials and are of much lesser relevance to patients, were not significantly different. However, rates of adverse events increased with the aminoglycoside. Nephrotoxicity was much more common with combination therapy.

Forty four trials compared a broad spectrum, usually novel, lactam with a "routine" combination regimen. Rates of appropriate antibiotic treatment with combination therapy and monotherapy were similar when reported. Fatality was not significantly different. Failures were significantly more common with combination therapy. Among all trials, we found no evidence for any potential prevention of infection by resistant isolates with combination therapy.

How should these findings be interpreted?
It can be debated which design appropriately examines the clinical interpretation of synergism, studies comparing same or different lactams. Synergism has been defined as a 2 log₁₀ or greater reduction in bacterial count with the combination versus that with each of the agents alone.¹³ In studies comparing the same lactam this is directly tested, but the effect of increasing the antibiotic spectrum cannot be separated from a synergistic effect. In studies comparing different lactams the spectrum of coverage was similar in both arms. However, synergism can be examined only indirectly. If we assume that the aminoglycoside offers more than its additional coverage, the combination arm should perform as well, or better, than the broader spectrum lactam monotherapy. With the former design we did not detect an advantage to the combination, while with the latter we found an advantage to monotherapy.

Weaknesses of the study
The quality of included studies was poor overall. We did not detect bias induced by any of the measures assessed. We could not obtain data on all cause fatality for 33% of studies. It is unlikely that missing results would shift the results for studies comparing the same lactam, but it is of concern that studies comparing different lactams may not detect important harm to patients.

Our assessment of treatment effects for patients with P aeruginosa, Gram negative, and blood infections relies on subgroup analysis. We did not detect an advantage for combination therapy among these patients. Only few patients with documented P aeruginosa infections could be evaluated. The types of infections addressed by included studies suggest that further infections were caused by this pathogen.

Does further evidence support our findings?
Suggestions for an advantage for combination treatment for P aeruginosa rely mostly on a prospective observational study.¹⁴ A similar study focusing on Klebsiella bacteraemia found an advantage for combination therapy only among patients with hypotension,¹⁵ while other studies have not found such an advantage.^16-19

In a comparison of lactam monotherapy with lactam-aminoglycoside combination therapy restricted to patients with neutropenia we found no advantage to combination treatment.²⁰ Although the approach to the management of patients with and without neutropenia is separated in clinical practice, this similarity supports a biological basis underlying our results.

What is already known on this topic Early appropriate antibiotic treatment for severe infections decreases mortality In vitro studies have shown that the bactericidal activity of a lactam may be enhanced by the addition of an aminogoycoside Prospective studies have suggested that the combination also has a clinical advantage What this study adds There is no difference in mortality when lactam-aminoglycoside combination therapy is compared with lactam monotherapy Clinical failure and renal toxicity are more common with combination therapy lactam-aminoglycoside combination therapy does not improve clinical outcomes in patients with severe infections

Implications for practice
Antibiotic treatment is nearly always instituted empirically and is often continued with no isolate to direct specific treatment. Most trials assessed this scenario and do not support a benefit for combination therapy. Clinicians may still opt for combination empirical treatment to increase the probability of appropriate empirical treatment, which has indeed been shown to improve survival.^{21 22} Current evidence suggests that aminoglycoside monotherapy may be inadequate for infections outside the urinary tract.^{16 23 24} Thus, for the purpose of enhancing antimicrobial spectrum, aminoglycosides may constitute a poor choice.

Implications for further research
Novel lactams should not be compared with older generation lactams or penicillins combined with aminoglycosides. The reason for further trials assessing the addition of an aminglycoside to a lactam seems dubious as well.

We included in our review a small subset of trials that assessed the value of addition of an aminoglycoside in Gram positive infections. lactam-aminoglycoside treatment is well ingrained in existing guidelines and clinical practice with these infections,²⁵ yet our results do not point to a clinical benefit with combination therapy. With these infections, further studies should assess whether the addition of an aminoglycoside is justified.

---

A full list of references to excluded studies can be found on bmj.com

This is the abridged version of an article that was posted on bmj.com on 2 March 2004: http://bmj.com/cgi/doi/10.1136/bmj.38028.520995.63

We thank the Cochrane Infectious Diseases Group for their support, review process, and help in obtaining papers; all the authors who responded for our requests for additional data; and Rika Fujiya, who translated the Japanese studies. The protocol for this review with the detailed search strategy and methods is published in the Cochrane Library.²⁶ The complete review will be published in the forthcoming issue of the Cochrane Library.

Contributors: See bmj.com

Funding: This work was supported by an EU 5th framework grant (TREAT project, grant No 1999-11459).

Competing interests: None declared.

Ethical approval: Not required.

References

1. Giamarellou H, Zissis NP, Tagari G, Bouzos J. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984;25: 534-6.[Abstract/Free Full Text]
2. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986;80: 126-37.[Web of Science][Medline]
3. Klastersky J, Meunier-Carpentier F, Prevost JM. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci 1977;273: 157-67.[Web of Science][Medline]
4. Klastersky J, Zinner SH. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 1982;4: 294-301.[Web of Science][Medline]
5. Den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1997;41: 95-100.[Abstract]
6. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999;27: S24-8.
7. Wu YL, Scott EM, Po AL, Tariq VN. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J Antimicrob Chemother 1999;44: 389-92.[Abstract/Free Full Text]
8. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163: 1730-54.[Free Full Text]
9. Moellering RS. Principles of anti-infective therapy. In: Mandell GL, Bennet JE, Dolin R, eds. Mandell, Douglas, and Bennet's principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000.
10. Leone M, Bourgoin A, Cambon S, Dubuc M, Albanese J, Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003;31: 462-7.[CrossRef][Web of Science][Medline]
11. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101: 1481-3.[Free Full Text]
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7: 177-88.[CrossRef][Web of Science][Medline]
13. Levison ME. Pharmacodynamics of antibacterial drugs. Infect Dis Clin North Am 2000;14: 281-91, vii.[CrossRef][Web of Science][Medline]
14. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteraemia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87: 540-6.[Web of Science][Medline]
15. Korvick JA, Bryan CS, Farber B, Beam TR Jr, Schenfeld L, Muder RR, et al. Prospective observational study of Klebsiella bacteraemia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992;36: 2639-44.[Abstract/Free Full Text]
16. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteraemia: a prospective, observational study. Antimicrob Agents Chemother 1997;41: 1127-33.[Abstract]
17. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteraemia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998;2: 211-5.[CrossRef][Medline]
18. Crabtree TD, Pelletier SJ, Gleason TG, Pruett TL, Sawyer RG. Analysis of aminoglycosides in the treatment of gram-negative infections in surgical patients. Arch Surg 1999;134: 1293-9.[Abstract/Free Full Text]
19. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteraemia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115: 585-90.
20. Paul M, Soares-Weiser K, Leibovici L. lactam monotherapy versus lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003;326: 1111.[Abstract/Free Full Text]
21. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115: 462-74.[Abstract/Free Full Text]
22. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244: 379-86.[CrossRef][Web of Science][Medline]
23. Bailey JA, Virgo KS, DiPiro JT, Nathens AB, Sawyer RG, Mazuski JE. Aminoglycosides for intra-abdominal infection: equal to the challenge? Surgical Infections 2002;3: 315-35.[CrossRef][Medline]
24. Bodey GP, Middleman E, Umsawadi T, Rodriguez V. Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer 1972;29: 1697-701.[CrossRef][Web of Science][Medline]
25. Bayer AS, Bolger AF, Taubert KA, Wilson W, Steckelberg J, Karchmer AW, et al. Diagnosis and management of infective endocarditis and its complications. Circulation 1998;98: 2936-48.[Free Full Text]
26. Paul M, Leibovici L, Grozinsky DG, Silbiger I, Soares-Weiser K. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for treating sepsis (protocol for Cochrane Review). Cochrane Library. Issue 2. Oxford: Update Software, 2003.

(Accepted 22 December 2003)

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Article

Adding amynoglycoside to lactam does not improve results
BMJ 2004 328: 0. [Full Text]

This article has been cited by other articles:

• Leibovici, L., Vidal, L., Paul, M. (2009). Aminoglycoside drugs in clinical practice: an evidence-based approach--authors' response. J Antimicrob Chemother 63: 1082-1083 [Full text]  
• Williams, K. J. (2009). Why monotherapy?. J Antimicrob Chemother 63: i18-i20 [Abstract] [Full text]  
• Leibovici, L., Vidal, L., Paul, M. (2009). Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 63: 246-251 [Abstract] [Full text]  
• Cairns, B. J., Payne, R. J. H. (2008). Bacteriophage Therapy and the Mutant Selection Window. Antimicrob. Agents Chemother. 52: 4344-4350 [Abstract] [Full text]  
• Gupta, R., Wargo, K. A. (2008). An Update on the Management of Nosocomial Pneumonia. Journal of Pharmacy Practice 21: 380-389 [Abstract]  
• Masterton, R. G., Galloway, A., French, G., Street, M., Armstrong, J., Brown, E., Cleverley, J., Dilworth, P., Fry, C., Gascoigne, A. D., Knox, A., Nathwani, D., Spencer, R., Wilcox, M. (2008). Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 62: 5-34 [Abstract] [Full text]  
• Leibovici, L., Paul, M. (2007). Aminoglycoside/{beta}-lactam combinations in clinical practice. J Antimicrob Chemother 60: 911-912 [Abstract] [Full text]  
• Freundlich, M., Thomsen, R. W., Pedersen, L., West, H., Schonheyder, H. C. (2007). Aminoglycoside treatment and mortality after bacteraemia in patients given appropriate empirical therapy: a Danish hospital-based cohort study. J Antimicrob Chemother 60: 1115-1123 [Abstract] [Full text]  
• Vidal, L., Gafter-Gvili, A., Borok, S., Fraser, A., Leibovici, L., Paul, M. (2007). Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 60: 247-257 [Abstract] [Full text]  
• Goldin, A. B., Sawin, R. S., Garrison, M. M., Zerr, D. M., Christakis, D. A. (2007). Aminoglycoside-Based Triple-Antibiotic Therapy Versus Monotherapy for Children With Ruptured Appendicitis. Pediatrics 119: 905-911 [Abstract] [Full text]  
• Beardsley, J. R., Williamson, J. C., Johnson, J. W., Ohl, C. A., Karchmer, T. B., Bowton, D. L. (2006). Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia.. Chest 130: 787-793 [Abstract] [Full text]  
• Porzecanski, I., Bowton, D. L. (2006). Diagnosis and treatment of ventilator-associated pneumonia.. Chest 130: 597-604 [Abstract] [Full text]  
• Micek, S. T., Lloyd, A. E., Ritchie, D. J., Reichley, R. M., Fraser, V. J., Kollef, M. H. (2005). Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment. Antimicrob. Agents Chemother. 49: 1306-1311 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Neutropenic or not?

Robert Townsend
bmj.com, 19 Mar 2004 [Full text]

Re: Neutropenic or not?

Mical Paul, et al.
bmj.com, 22 Mar 2004 [Full text]

severe sepsis versus patients at lower risk of death?

Joseph C Watine
bmj.com, 23 Mar 2004 [Full text]

Are children, sometimes, little adults as well ?

Jean-francois Hartmann
bmj.com, 24 Mar 2004 [Full text]

Beta-lactam and aminoglycoside combination therapy. The role of different aminoglycoside dosing regimens.

Peter A Riley
bmj.com, 25 Mar 2004 [Full text]

A case for antibiotic combination therapy against pseudomonas infection remains

RICHARD P COOKE, et al.
bmj.com, 2 Apr 2004 [Full text]

Beta-lactam/aminoglycoside combination therapy should still be considered for patients with severe sepsis

Gavin D Barlow
bmj.com, 7 Apr 2004 [Full text]

Beta-lactam/ aminoglycoside combination therapy in severe P. aeruginosa infections?

Bart J.M. Vlaminckx, et al.
bmj.com, 22 Apr 2004 [Full text]

Use of aminoglycosides with beta-lactams

Christopher D Settle
bmj.com, 23 Apr 2004 [Full text]

Simplistic and inaccurate about anitbiotics

Gunnar S Simonsen, et al.
bmj.com, 28 Jun 2004 [Full text]

Is combination therapy with betalactam plus aminoglycoside (AGL) improving the outcome of nosocomial meningitis in children? (letter)

Vladimir Krcmery, et al.
bmj.com, 1 Apr 2005 [Full text]

Online poll

Find out more>>